drugset / Trial / NCT06559488

IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes

NCT06559488

RandomizedParallel-groupSingle-blindTreatment

Summary

Recurrent vitreous hemorrhage following pars plana vitrectomy (PPV) for proliferative diabetic retinopathy remains a significant complication with reported incidence ranging from 11 to 75%. Early and late recurrences are associated with various factors, including residual blood, fibrovascular tissue, and neovascularization. Despite attempts to reduce this complication with therapies like anti-fibrinolytic agents, gas tamponade, and peripheral cryotherapy, the outcomes remain unsatisfactory.

Timeline

Start
2018-04-02
Primary completion
2019-03-31
Completion
2019-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 1.25 mg Intravitreal

Indications